December 21, 2016 / 1:23 PM / 8 months ago

BRIEF-Inovio's zika vaccine generates robust immune responses in first human study

Dec 21 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio's zika vaccine generates robust immune responses in first human study

* Inovio Pharma- vaccine was well tolerated, no significant safety concerns noted in any of 40 subjects out to 14 weeks from initiation of dosing Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below